Informations générales (source: ClinicalTrials.gov)
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy for the Follow-up of Patients With Transthyretin Amyloidosis Treated With Tafamidis
Interventional
N/A
GCS Ramsay Santé pour l'Enseignement et la Recherche (Voir sur ClinicalTrials)
février 2021
décembre 2025
09 mai 2026
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant
reduction in mortality. The Perugini score is commonly used on planar bone scans to
differentiate cardiac ATTR from other amyloidosis or normal patients but fails to
evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have
been suggested to evaluate the amyloid burden, there a need for quantitative methods for
longitudinal assessment of the disease.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital privé Le Bois - 59000 - Lille - France | Frederic Mouquet | Contact (sur clinicalTrials) | |||
Critères
Tous
- Patient, male or female, over 18 years of age
- Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy
- Patient with signed consent
Exclusion Criteria:
- Patients with systemic AL amyloidosis
- Protected patient : major under guardianship, tutorship or other legal protection,
deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding woman